IDH1 and acute myeloid leukemia: Already, hypomethylating agents, such as azacytidine and decitabine, and IDH inhibitors, are the main therapeutic treatments for older AML patients who are unable to tolerate chemotherapy and relapsed/refractory AML patients harbouring an IDH mutation, respectively (recently reviewed in [104]).